RxDoctor Payments Data

Jeffrey Grant, MD

Internal Medicine · West Hollywood, CANPI 1346304870

Payments from drug & device makers

$805in general payments, 2019–2025

Across 21 payments — averaging $38.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$566
  • Novo Nordisk$105
  • AstraZeneca$41
  • Pfizer$36
  • AbbVie$34
  • Takeda Pharmaceuticals U.S.A., Inc.$23

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$805 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$116,782
Medicare patients
281
Services billed
2,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$52,476
JardianceEmpagliflozin55$42,248
EliquisApixaban36$39,071
TrulicityDulaglutide25$27,123
FarxigaDapagliflozin Propanediol20$19,448
MounjaroTirzepatide16$16,852
Repatha SureclickEvolocumab11$13,661
EdarbiAzilsartan Medoxomil38$12,015
XareltoRivaroxaban15$9,853
SynthroidLevothyroxine Sodium75$6,340
InvokanaCanagliflozin11$6,056
Ezetimibe146$4,607
Atorvastatin Calcium473$4,214
Rosuvastatin Calcium212$3,373
AvaproIrbesartan12$3,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$105$52,47648 claims
PfizerEliquis, Paxlovid$36$40,50151 claims
AstraZenecaFarxiga$41$19,44820 claims
AbbVieSynthroid$34$6,34075 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →